Total Payments
$80,152
2024 Payments
$8,764
Companies
46
Transactions
742
Medicare Patients
8,601
Medicare Billing
$1.1M
Payment Breakdown by Category
Other$53,230 (66.4%)
Food & Beverage$14,152 (17.7%)
Consulting$7,128 (8.9%)
Travel$4,549 (5.7%)
Education$1,093 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $53,230 | 36 | 66.4% |
| Food and Beverage | $14,152 | 668 | 17.7% |
| Consulting Fee | $7,128 | 2 | 8.9% |
| Travel and Lodging | $4,549 | 17 | 5.7% |
| Education | $1,093 | 19 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35,585 | 59 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $30,047 | 122 | $0 (2024) |
| INTUITIVE SURGICAL, INC. | $3,239 | 12 | $0 (2024) |
| Veran Medical Technologies, Inc. | $1,351 | 9 | $0 (2020) |
| Electromed, Inc. | $1,333 | 102 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $1,137 | 57 | $0 (2024) |
| Mylan Specialty L.P. | $965.26 | 46 | $0 (2024) |
| ABBVIE INC. | $835.18 | 36 | $0 (2024) |
| GlaxoSmithKline, LLC. | $773.28 | 59 | $0 (2024) |
| Genentech USA, Inc. | $706.28 | 40 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,764 | 97 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,051) |
| 2023 | $15,337 | 138 | Boehringer Ingelheim Pharmaceuticals, Inc. ($11,688) |
| 2022 | $10,833 | 103 | Boehringer Ingelheim Pharmaceuticals, Inc. ($4,929) |
| 2021 | $25,752 | 43 | AstraZeneca Pharmaceuticals LP ($20,160) |
| 2020 | $13,320 | 88 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,093) |
| 2019 | $1,799 | 103 | Genentech USA, Inc. ($319.16) |
| 2018 | $3,386 | 122 | Veran Medical Technologies, Inc. ($1,150) |
| 2017 | $961.50 | 48 | Mallinckrodt LLC ($259.68) |
All Payment Transactions
742 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $21.30 | General |
| Category: HFCWO | ||||||
| 12/12/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: CRITICAL CARE | ||||||
| 12/09/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/05/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $22.35 | General |
| Category: HFCWO | ||||||
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $30.05 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/26/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Education | In-kind items and services | $319.00 | General |
| Category: SURGERY | ||||||
| 11/22/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $7.98 | General |
| Category: HFCWO | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $34.10 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/14/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: Inflammation | ||||||
| 11/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/11/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $33.36 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/05/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Education | In-kind items and services | $460.68 | General |
| Category: SURGERY | ||||||
| 11/04/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO | Food and Beverage | In-kind items and services | $27.03 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/04/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $22.21 | General |
| Category: HFCWO | ||||||
| 11/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: Cardio-pulmonary | ||||||
| 10/24/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/17/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $30.88 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/08/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $36.61 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/01/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $20.43 | General |
| Category: HFCWO | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $80.99 | General |
| Category: Respiratory | ||||||
| 09/17/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: RESPIRATORY | ||||||
| 09/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,510.00 | General |
| Category: RESPIRATORY | ||||||
| 09/10/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO | Food and Beverage | In-kind items and services | $32.07 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/06/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $14.51 | General |
| Category: HFCWO | ||||||
| 09/05/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $19.94 | General |
| Category: HFCWO | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 2,502 | 5,096 | $1.2M | $356,284 |
| 2022 | 21 | 2,207 | 3,601 | $1.0M | $293,577 |
| 2021 | 22 | 2,219 | 4,766 | $911,483 | $283,424 |
| 2020 | 24 | 1,673 | 2,599 | $677,224 | $195,175 |
Total Patients
8,601
Total Services
16,062
Medicare Billing
$1.1M
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 355 | 947 | $254,913 | $88,123 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 432 | 704 | $185,666 | $65,494 | 35.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 266 | 295 | $154,462 | $38,969 | 25.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 210 | 438 | $82,322 | $27,562 | 33.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 18 | 18 | $104,974 | $21,144 | 20.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 132 | 160 | $56,957 | $20,815 | 36.5% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 24 | 25 | $34,229 | $12,550 | 36.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 81 | 81 | $41,134 | $12,360 | 30.0% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 150 | 174 | $57,437 | $10,747 | 18.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 85 | 85 | $35,911 | $10,326 | 28.8% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 168 | 170 | $24,001 | $7,118 | 29.7% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 168 | 170 | $24,162 | $7,060 | 29.2% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 13 | 13 | $16,911 | $6,154 | 36.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 169 | 171 | $26,801 | $4,773 | 17.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 40 | 40 | $14,117 | $3,930 | 27.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 17 | 21 | $14,856 | $3,687 | 24.8% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 16 | 1,200 | $13,200 | $3,497 | 26.5% |
| G0400 | Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | Office | 2023 | 17 | 32 | $8,088 | $2,316 | 28.6% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 18 | 18 | $5,314 | $1,882 | 35.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 23 | 47 | $4,758 | $1,869 | 39.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 15 | 122 | $6,451 | $1,348 | 20.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 22 | $3,925 | $1,343 | 34.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 17 | 78 | $4,086 | $1,333 | 32.6% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 14 | 14 | $9,224 | $1,140 | 12.4% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 32 | 51 | $1,907 | $743.97 | 39.0% |
About Dr. Hammad Qureshi, M.D
Dr. Hammad Qureshi, M.D is a Pulmonary Disease healthcare provider based in The Woodlands, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1063618874.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hammad Qureshi, M.D has received a total of $80,152 in payments from pharmaceutical and medical device companies, with $8,764 received in 2024. These payments were reported across 742 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($53,230).
As a Medicare-enrolled provider, Qureshi has provided services to 8,601 Medicare beneficiaries, totaling 16,062 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location The Woodlands, TX
- Active Since 06/27/2007
- Last Updated 11/21/2014
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1063618874
Products in Payments
- OFEV (Drug) $35,322
- BREZTRI (Drug) $24,980
- BREZTRI AEROSPHERE (Drug) $3,551
- Da Vinci Surgical System (Device) $3,111
- Spin (Device) $1,351
- SMARTVEST (Device) $1,333
- DUPIXENT (Biological) $717.57
- UPTRAVI (Drug) $648.38
- ACTHAR (Biological) $606.39
- TEFLARO (Drug) $552.10
- SYMBICORT (Drug) $540.76
- AVYCAZ (Drug) $491.75
- Xolair (Biological) $490.34
- YUPELRI (Drug) $483.48
- TRELEGY ELLIPTA (Drug) $400.14
- TEZSPIRE (Biological) $378.78
- Yupelri (Drug) $342.72
- remede System (Device) $299.43
- FASENRA (Biological) $289.54
- OPSUMIT (Drug) $270.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.